Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus DEPAKENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREBYX versus DEPAKENE.
CEREBYX vs DEPAKENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates histone deacetylase activity.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
Oral: Initial 15 mg/kg/day divided into 1-3 doses, increase by 5-10 mg/kg/day weekly; typical maintenance 30-60 mg/kg/day. Intravenous: Same total daily dose as oral, administered as continuous infusion or divided q6h.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
10-16 hours (monotherapy); 5-9 hours in patients on enzyme-inducing co-medications; prolonged in hepatic impairment (up to 30 hours) or neonates.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Renal: <3% unchanged; primarily hepatic metabolism via glucuronidation (50%) and beta-oxidation (40%), with metabolites excreted renally. Fecal: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant